Abstract
Background Genetic and lifestyle factors are related to the risk of cancer, but it is unclear whether a healthy lifestyle can offset genetic risk. Our aim was to investigate this for 13 cancer types using data from the UK Biobank prospective cohort.
Methods In 2006-2010, participants aged 37-73 years were assessed and followed until 2015-2019. Analyses were restricted to those of European ancestries with no history of malignant cancer (n=195,822). Polygenic risk scores (PRSs) were computed for 13 cancer types and these cancers combined (‘overall cancer’), and a healthy lifestyle score was calculated from current recommendations. Relationships with cancer incidence were examined using Cox regression, adjusting for relevant confounders. Interactions between HLI and PRSs were assessed.
Results There were 15,240 incident cancers during the 1,926,987 person-years of follow-up (median follow-up= 10.2 years). After adjusting for confounders, an unhealthy lifestyle was associated with a higher risk of overall cancer [lowest vs highest tertile hazard ratio (95% confidence interval) = 1.32(1.26, 1.37)] and eight cancer types. The greatest increased risks were seen for cancers of the lung [3.5(2.96,4.15)], bladder [2.03 (1.57, 2.64)], and pancreas [1.98 (1.54,2.55)]. Positive additive interactions were observed, suggesting a healthy lifestyle may partially offset genetic risk of colorectal, breast, and pancreatic cancers, and may completely offset genetic risk of lung and bladder cancers.
Conclusions A healthy lifestyle is beneficial for most cancers and may offset genetic risk of some cancers. These findings have important implications for those genetically predisposed to these cancers and population strategies for cancer prevention.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by Tour de Cure [RSP-013-18/19]; and the Australian Government Medical Research Future Fund (MRFF) as part of the Rapid Applied Research Translation program. This project is part of the work being undertaken by Health Translation SA [MRF9100005].
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study is a secondary analysis of UK Biobank data. The UK Biobank cohort study was approved by the National Health Service North West Multi-centre Research Ethics Committee (11/NW/0382), the National Information Governance Board for Health and Social Care in England and Wales, and the Community Health Index Advisory Group in Scotland.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
This research utilizes data from the UK Biobank resource (application number 20175) which is available directly from the UK Biobank upon submission of a data request proposal. See https://www.ukbiobank.ac.uk.
